The unique pancreatic stellate cell gene expression signatures are associated with the progression from acute to chronic pancreatitis
Cheng Hu,Liyuan Yin,Zhiyao Chen,Richard T. Waldron,Aurelia Lugea,Yiyun Lin,Xiaoqian Zhai,Li Wen,Yuan-Ping Han,Stephen J. Pandol,Lihui Deng,Qing Xia
DOI: https://doi.org/10.1016/j.csbj.2021.11.031
IF: 6.155
2021-01-01
Computational and Structural Biotechnology Journal
Abstract:Chronic pancreatitis (CP) is characterized by irreversible fibro-inflammatory changes induced by pancreatic stellate cell (PSC). Unresolved or recurrent injury causes dysregulation of biological process following AP, which would cause CP. Here, we systematically identify genes whose expressions are unique to PSC by comparing transcriptome profiles among total pancreas, pancreatic stellate, acinar, islet and immune cells. We then identified candidate genes and correlated them with the pancreatic disease continuum by performing intersection analysis among total PSC and activated PSC genes, and genes persistently differentially expressed during acute pancreatitis (AP) recovery. Last, we examined the association between candidate genes and AP, and substantiated their potential as biomarkers in experimental AP and recurrent AP (RAP) models. A total of 68 genes were identified as highly and uniquely expressed in PSC. The PSC signatures were highly enriched with extracellular matrix remodeling genes and were significantly enriched in AP pancreas compared to healthy control tissues. Among PSC signature genes that comprised a fibrotic phenotype, 10 were persistently differentially expressed during AP recovery. SPARC was determined as a candidate marker for the pancreatic disease continuum, which was not only persistently differentially expressed even five days after AP injury, but also highly expressed in two clinical datasets of CP. Sparc was also validated as highly elevated in RAP compared to AP mice. This work highlights the unique transcriptional profiles of PSC. These PSC signatures' expression may help to identify patients with high risk of AP progression to CP.
biochemistry & molecular biology
What problem does this paper attempt to address?